Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study
Jin Li, Ruihua Xu, Shukui Qin, Tianshu Liu, Hongming Pan, Jianming Xu, Feng Bi, Robert Lim, Suzhan Zhang, Yi Ba, Yuxian Bai, Nanfeng Fan, Akihito Tsuji, Kun-Huei Yeh, Brigette Ma, Vivian Wei, Dongmei Shi, Emmanuelle Magherini, Lin Shen, Jin Li, Ruihua Xu, Shukui Qin, Tianshu Liu, Hongming Pan, Jianming Xu, Feng Bi, Robert Lim, Suzhan Zhang, Yi Ba, Yuxian Bai, Nanfeng Fan, Akihito Tsuji, Kun-Huei Yeh, Brigette Ma, Vivian Wei, Dongmei Shi, Emmanuelle Magherini, Lin Shen
Abstract
Aim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. The primary end point was progression-free survival.
Results: The intention-to-treat population comprised 332 patients. A clinical supply misallocation resulted in 198/332 (60%) patients receiving at least one cycle of misallocated treatment. Nevertheless, the addition of aflibercept to FOLFIRI was shown to improve progression-free survival (hazard ratio: 0.629; 95% CI: 0.488-0.812). Adverse events were in line with expectations.
Conclusion: The beneficial treatment effect associated with the addition of aflibercept to FOLFIRI was confirmed in Asian patients with pretreated metastatic colorectal cancer.
Keywords: Asia-Pacific; FOLFIRI; aflibercept; mCRC; oxaliplatin-pretreated.
Source: PubMed